Neumora to Host Roundtable on Navacaprant's Potential in Neuropsychiatric Disorders

Neumora Therapeutics, Inc., a biopharmaceutical company specializing in brain disease treatments, has scheduled a roundtable discussion on the current neuropsychiatric treatment landscape and the role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. This event will occur on Thursday, September 12 at 8:00 a.m. ET and will feature prominent experts in the field.

Henry Gosebruch, Neumora's CEO, expressed optimism about the upcoming discussion, highlighting the scientific community’s interest in KORAs for various neuropsychiatric conditions. He emphasized the company’s dedication to advancing navacaprant, a promising therapeutic candidate currently in Phase 3 trials for major depressive disorder (MDD) and Phase 2 trials for bipolar depression (BPD). Gosebruch believes navacaprant could significantly impact treatments for these serious brain disorders and anticipates reporting initial data from the KOASTAL-1 study by the end of the year.

The program for the roundtable will cover several key topics:

1. Global Brain Disease: Neumora’s Mission and Pipeline - Dr. Josh Pinto, the Chief Financial Officer, will discuss the company’s overarching mission and its diverse pipeline of brain disease treatments.
2. The Role of Kappa Opioid Receptors in MDD and Overview of Navacaprant Phase 2 Data - Bill Aurora, Pharm.D., the Chief Strategy Officer, will delve into the function of kappa opioid receptors in MDD and present data from navacaprant’s Phase 2 trials.
3. Indication Opportunities for Navacaprant: MDD, BPD, and Beyond - Dr. Rob Lenz, Head of Research and Development, will explore the potential uses of navacaprant beyond its current indications.
4. Fireside Chat: A Discussion on the Neuropsychiatric Treatment Landscape and Opportunity for Navacaprant - Esteemed medical professionals, including Dr. Roger McIntyre from the University of Toronto, Dr. Sanjay Mathew from Baylor College of Medicine, and Dr. John Krystal from Yale University School of Medicine, will engage in a detailed discussion on current treatment landscapes and future possibilities for navacaprant.
5. Company Outlook: A Look Ahead - CEO Henry Gosebruch will wrap up with insights into Neumora’s future directions and expectations.

Navacaprant (NMRA-140) is a selective, innovative, once-daily KOR antagonist aimed at treating MDD and other neuropsychiatric conditions. The therapeutic approach has been supported by three independent clinical studies. Neumora is actively enrolling participants in its Phase 3 KOASTAL program, which includes several replicate studies—KOASTAL-1, KOASTAL-2, and KOASTAL-3—focused on assessing navacaprant’s efficacy and safety in MDD treatment. Additionally, a Phase 2 study for bipolar depression began in May 2024.

Neumora plans to release results from the KOASTAL-1 trial in the fourth quarter of 2024, with further data from KOASTAL-2 and KOASTAL-3 expected in the first half of 2025. Results from the Phase 2 BPD study are anticipated in the latter half of 2025.

Founded to address the global brain disease crisis, Neumora Therapeutics aims to revolutionize neuroscience drug development. The company’s pipeline includes seven programs targeting novel mechanisms for various underserved neuropsychiatric and neurodegenerative disorders. Neumora integrates translational, clinical, and computational tools to support precision medicine approaches, striving to improve treatment outcomes and the quality of life for patients with brain diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!